Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 and JAB-3312 vs Tislelizumab + Chemotherapy in First-Line KRAS G12C Mutated Advanced Non-squamous NSCLC
NCT06416410Phase 3Recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glecirasib and sitneprotafib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Allist Pharmaceuticals. Primary endpoint: Progression-free Survival up to 4 years. Started Aug 2024; status: recruiting.
02
Drugs
glecirasibsitneprotafib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06416410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416410.